TISIDB

Summary
Symbol	JMJD6
Name	jumonji domain containing 6
Aliases	PTDSR1; KIAA0585; PTDSR; phosphatidylserine receptor; PSR; histone arginine demethylase JMJD6; jmjC domain-c ......
Chromosomal Location	17q25
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus, nucleoplasm. Nucleus, nucleolus. Note=Mainly found throughout the nucleoplasm outside of regions containing heterochromatic DNA, with some localization in nucleolus. During mitosis, excluded from the nucleus and reappears in the telophase of the cell cycle.
Domain	PF02373 JmjC domain
Function	Dioxygenase that can both act as a histone arginine demethylase and a lysyl-hydroxylase. Acts as a lysyl-hydroxylase that catalyzes 5-hydroxylation on specific lysine residues of target proteins such as U2AF2/U2AF65 and LUC7L2. Acts as a regulator of RNA splicing by mediating 5-hydroxylation of U2AF2/U2AF65, affecting the pre-mRNA splicing activity of U2AF2/U2AF65. In addition to peptidyl-lysine 5-dioxygenase activity, may act as an RNA hydroxylase, as suggested by its ability to bind single strand RNA. Also acts as an arginine demethylase which demethylates histone H3 at 'Arg-2' (H3R2me) and histone H4 at 'Arg-3' (H4R3me), thereby playing a role in histone code. However, histone arginine demethylation may not constitute the primary activity in vivo. Has no histone lysine demethylase activity. Required for differentiation of multiple organs during embryogenesis. Acts as a key regulator of hematopoietic differentiation: required for angiogenic sprouting by regulating the pre-mRNA splicing activity of U2AF2/U2AF65. Seems to be necessary for the regulation of macrophage cytokine responses.

> Gene Ontology [ TOP ]
Biological Process	GO:0000375 RNA splicing, via transesterification reactions GO:0000377 RNA splicing, via transesterification reactions with bulged adenosine as nucleophile GO:0000398 mRNA splicing, via spliceosome GO:0001525 angiogenesis GO:0001654 eye development GO:0001655 urogenital system development GO:0001822 kidney development GO:0002040 sprouting angiogenesis GO:0002262 myeloid cell homeostasis GO:0002274 myeloid leukocyte activation GO:0002521 leukocyte differentiation GO:0006397 mRNA processing GO:0006482 protein demethylation GO:0006909 phagocytosis GO:0006910 phagocytosis, recognition GO:0007159 leukocyte cell-cell adhesion GO:0007423 sensory organ development GO:0007507 heart development GO:0008037 cell recognition GO:0008214 protein dealkylation GO:0008380 RNA splicing GO:0016570 histone modification GO:0016577 histone demethylation GO:0017185 peptidyl-lysine hydroxylation GO:0018126 protein hydroxylation GO:0018205 peptidyl-lysine modification GO:0018395 peptidyl-lysine hydroxylation to 5-hydroxy-L-lysine GO:0030098 lymphocyte differentiation GO:0030099 myeloid cell differentiation GO:0030217 T cell differentiation GO:0030218 erythrocyte differentiation GO:0030323 respiratory tube development GO:0030324 lung development GO:0033077 T cell differentiation in thymus GO:0034101 erythrocyte homeostasis GO:0042110 T cell activation GO:0042116 macrophage activation GO:0043010 camera-type eye development GO:0043277 apoptotic cell clearance GO:0043484 regulation of RNA splicing GO:0043654 recognition of apoptotic cell GO:0048024 regulation of mRNA splicing, via spliceosome GO:0048514 blood vessel morphogenesis GO:0048821 erythrocyte development GO:0048872 homeostasis of number of cells GO:0050684 regulation of mRNA processing GO:0060041 retina development in camera-type eye GO:0060541 respiratory system development GO:0061515 myeloid cell development GO:0070077 histone arginine demethylation GO:0070078 histone H3-R2 demethylation GO:0070079 histone H4-R3 demethylation GO:0070486 leukocyte aggregation GO:0070489 T cell aggregation GO:0070988 demethylation GO:0071593 lymphocyte aggregation GO:0071594 thymocyte aggregation GO:0072001 renal system development GO:1903311 regulation of mRNA metabolic process
Molecular Function	GO:0003727 single-stranded RNA binding GO:0005506 iron ion binding GO:0016705 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016706 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, 2-oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors GO:0032451 demethylase activity GO:0032452 histone demethylase activity GO:0033746 histone demethylase activity (H3-R2 specific) GO:0033749 histone demethylase activity (H4-R3 specific) GO:0051213 dioxygenase activity GO:0070815 peptidyl-lysine 5-dioxygenase activity
Cellular Component	-

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-3247509: Chromatin modifying enzymes R-HSA-4839726: Chromatin organization R-HSA-3214842: HDMs demethylate histones

Summary
Symbol	JMJD6
Name	jumonji domain containing 6
Aliases	PTDSR1; KIAA0585; PTDSR; phosphatidylserine receptor; PSR; histone arginine demethylase JMJD6; jmjC domain-c ......
Chromosomal Location	17q25
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between JMJD6 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	JMJD6
Name	jumonji domain containing 6
Aliases	PTDSR1; KIAA0585; PTDSR; phosphatidylserine receptor; PSR; histone arginine demethylase JMJD6; jmjC domain-c ......
Chromosomal Location	17q25
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of JMJD6 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	logFC: -2.95; FDR: 0.00942	Resistant to T cell-mediated killing
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	JMJD6
Name	jumonji domain containing 6
Aliases	PTDSR1; KIAA0585; PTDSR; phosphatidylserine receptor; PSR; histone arginine demethylase JMJD6; jmjC domain-c ......
Chromosomal Location	17q25
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of JMJD6 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.086	0.724
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.252	0.892
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.337	0.812
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.189	0.56
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.588	0.721
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.322	0.887
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.084	0.82
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.023	0.986
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.24	0.869
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.397	0.785
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.902	0.671
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.012	0.844

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of JMJD6 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	7.4	1.4	6	0.177
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	7.4	1.7	5.7	0.231
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	5.9	-5.9	0.447
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	9.1	-9.1	0.458
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	JMJD6
Name	jumonji domain containing 6
Aliases	PTDSR1; KIAA0585; PTDSR; phosphatidylserine receptor; PSR; histone arginine demethylase JMJD6; jmjC domain-c ......
Chromosomal Location	17q25
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of JMJD6. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	JMJD6
Name	jumonji domain containing 6
Aliases	PTDSR1; KIAA0585; PTDSR; phosphatidylserine receptor; PSR; histone arginine demethylase JMJD6; jmjC domain-c ......
Chromosomal Location	17q25
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of JMJD6. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by JMJD6. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	JMJD6
Name	jumonji domain containing 6
Aliases	PTDSR1; KIAA0585; PTDSR; phosphatidylserine receptor; PSR; histone arginine demethylase JMJD6; jmjC domain-c ......
Chromosomal Location	17q25
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of JMJD6. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	JMJD6
Name	jumonji domain containing 6
Aliases	PTDSR1; KIAA0585; PTDSR; phosphatidylserine receptor; PSR; histone arginine demethylase JMJD6; jmjC domain-c ......
Chromosomal Location	17q25
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of JMJD6 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	JMJD6
Name	jumonji domain containing 6
Aliases	PTDSR1; KIAA0585; PTDSR; phosphatidylserine receptor; PSR; histone arginine demethylase JMJD6; jmjC domain-c ......
Chromosomal Location	17q25
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between JMJD6 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	JMJD6
Name	jumonji domain containing 6
Aliases	PTDSR1; KIAA0585; PTDSR; phosphatidylserine receptor; PSR; histone arginine demethylase JMJD6; jmjC domain-c ......
Chromosomal Location	17q25
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting JMJD6 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse JMJD6